Evidence map›Paper›PMID 33542347›Full record

ArticleScientific reports2021

Menaquinone 4 increases plasma lipid levels in hypercholesterolemic mice.

Jonna Weisell, Anna-Kaisa Ruotsalainen, Juha Näpänkangas, Matti Jauhiainen, Jaana Rysä

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Experimental and therapeutic medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jonna WeisellSchool of Pharmacy, University of Eastern Finland, POB 1627, 70211, Kuopio, Finland.
Anna-Kaisa RuotsalainenA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Juha NäpänkangasDepartment of Pathology, University of Oulu, Oulu University Hospital, Oulu, Finland.
Matti JauhiainenMinerva Foundation Institute for Medical Research, Helsinki, Finland.
Jaana RysäSchool of Pharmacy, University of Eastern Finland, POB 1627, 70211, Kuopio, Finland. jaana.rysa@uef.fi.
University of Eastern Finland · FIMinerva Foundation · FIUniversity of Oulu · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In calcific aortic valve disease (CAVD) progressive valvular calcification causes aortic valve dysfunction. CAVD has several risk factors such as age and dyslipidemia. Vitamin K was shown to inhibit vascular calcification in mice and valvular calcification in patients with CAVD. We studied the effect of menaquinone 4 (MK4/vitamin K2) on valvular calcification in the hypercholesterolemic mouse model of CAVD. LDLr

Indexed as

AnimalsAortic ValveAortic Valve StenosisApolipoproteins BCalcinosisDisease Models, AnimalHumansHypercholesterolemiaLipidsLipoproteins, LDLMiceMice, KnockoutReceptors, LDLRisk FactorsTriglyceridesVitamin K 2Apolipoproteins BLipidsLipoproteins, LDLReceptors, LDLTriglyceridesVitamin K 2

Identifiers

PMID33542347
PMCPMC7862223
OpenAlexW3126364607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.